Rapid Micro Biosystems Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -94.6% over 5Y.
today you would have $60.10▼ -94.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $2.90 | $0.90 | $0.74 | $1.13 | $10.64 | |
| P/S | 2.8x | 3.9x | 1.4x | 1.4x | 2.8x | 9.1x |
| P/B | 0.5x | 3.9x | 0.5x | 0.3x | 0.3x | 1.0x |
| EPS | -$1.05 | -$1.08 | -$1.22 | -$1.43 | -$3.94 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CVRXCVRx, Inc. | $2.95 | — | 3.9x | — | -133.44% | $78.59M |
| TELOTelomir Pharmaceuticals, Inc. | $1.14 | — | 7.9x | — | -213.10% | $78.4M |
| TENXTenax Therapeutics Inc | $2.13 | — | 0.9x | — | -59.80% | $79.71M |
| CINGCingulate Inc. | $5.33 |
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Company description provided by Yahoo Finance.
| Profit margin | -232.99% | -140.30% | -167.16% | -232.99% | -354.91% | -316.48% |
| ROE | -44.47% | -141.91% | -62.23% | -44.47% | -37.04% | -33.27% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 3.2x |
| — |
| -198.74% |
| $77.44M |
| GANXGain Therapeutics, Inc. | $1.77 | — | 6.8x | — | -268.30% | $77.25M |
| APLMApollomics Inc. | $26.60 | — | — | — | -1305.37% | $77.04M |